Qiwi PLC (NASDAQ:QIWI) has received a consensus recommendation of “Buy” from the eight analysts that are covering the stock, AnalystRatings.NET reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $42.53. Qiwi PLC (NASDAQ:QIWI) shares after opening at $34.38 moved to $34.61 on last trade day and at the end of the day closed at $30.78. Company price to sales ratio in past twelve months was calculated as 5.28 and price to cash ratio as 7.76. Qiwi PLC (NASDAQ:QIWI) showed a negative weekly performance of -13.64%.
The China Ming Yang Wind Power Group Ltd (NYSE:MY) is a wind turbine manufacturer in China, focusing on designing, manufacturing, selling and servicing megawatt-class wind turbines. The Company’s products consist of basic models of wind turbines, each with a rated power capacity of 1.5 megawatt (MW); wind turbines with a rated power capacity of 2.0MW, and 2.5/3.0MW SCD wind turbines. China Ming Yang Wind Power Group Ltd (NYSE:MY) shares fell -11.00% in last trading session and ended the day on $2.67. MY return on equity ratio is recorded as -6.70% and its return on assets is -2.10%. China Ming Yang Wind Power Group Ltd (NYSE:MY) yearly performance is 122.50%.
In trading on Thursday, shares of Organovo Holdings Inc (NYSEMKT:ONVO) entered into oversold territory, hitting an RSI reading of 25.2, after changing hands as low as $7.51 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 52.2. A bullish investor could look at ONVO’s 25.2. Organovo Holdings Inc (NYSEMKT:ONVO) shares moved down -10.84% in last trading session and was closed at $7.24, while trading in range of $7.16-$8.01. Organovo Holdings Inc (NYSEMKT:ONVO) year to date performance is -34.60%.
Israeli companies have raised $1 billion on the US capital market since the beginning of the year, including offers to sell by shareholders. The precise figure is $844.3 million, but taking into account the secondary offering by Wix.com Ltd. (Nasdaq: WIX), the planned offering by BioBlast Pharma Ltd. (the only Israeli life sciences company that has not yet held an IPO on the basis of its public prospectus), and if the over-allotment options in the various offerings are exercised, the total amount raised will reach $1 billion.Wix.Com Ltd (NASDAQ:WIX) weekly performance is -23.95%. On last trading day company shares ended up $20.20. Wix.Com Ltd (NASDAQ:WIX) distance from 50-day simple moving average is -27.61%. Analysts mean target price for the company is $37.25.